Preventing PSC recurrence after liver transplant
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had a liver transplant for PSC or PSC-related liver cancer between 1 and 7 years ago.
- You do not have signs of PSC recurrence now.
- You have at least one of these risk factors: your transplant was for bile duct cancer, you have inflammatory bowel disease, you had a cytomegalovirus infection after transplant, or you had acute rejection after transplant.
- You live within a 3-hour drive of Mayo Clinic Arizona or can travel there every 4 months at your own cost.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
This study uses a PET/MRI scan to take detailed pictures of the liver and bile ducts in people with PSC. The goal is to better understand the disease and possibly find new ways to track it.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.